Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 8/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490273 | 0.91 | GCGR (0.43) | GCGRSCN2ASCN10ACTNNB1TCF7L2 | |
| SCHEMBL6489350 | 0.90 | APOB (0.43) | — | |
| SCHEMBL6501443 | 0.85 | PIK3CA (0.40) | GCGRSCN2ASCN10AF10SMN1; SMN2 | |
| SCHEMBL6492232 | 0.85 | CYP3A4 (0.41) | ALDH1A1 | |
| SCHEMBL6487481 | 0.84 | F10 (0.43) | CTNNB1TCF7L2F10SMN1; SMN2 | |
| SCHEMBL6489781 | 0.82 | L3MBTL1 (0.47) | SMN1; SMN2 | |
| SCHEMBL6500632 | 0.82 | ITGB1 (0.44) | GCGRSCN2ASCN10AF10 | |
| SCHEMBL6489345 | 0.81 | GCGR (0.51) | GCGRCTNNB1TCF7L2SMN1; SMN2 | |
| SCHEMBL6493011 | 0.80 | MTTP (0.48) | — | |
| SCHEMBL6497868 | 0.80 | PIK3CA (0.42) | SMN1; SMN2PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | GCGR 1784/4885SCN2A 614/4885SCN10A 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.